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 31 
Abstract 32 
Context: Several randomized clinical trials (RCTs) have recently tested the early addition 33 
of docetaxel to androgen deprivation therapy (ADT) in hormone-sensitive, metastatic 34 
prostate cancer.  35 
Objective: To perform a systematic review and meta-analysis of RCTs evaluating the 36 
combination of docetaxel and ADT in hormone-sensitive, metastatic prostate cancer. 37 
Primary endpoint was overall survival (OS). Secondary endpoint was progression-free 38 
survival. Exploratory subgroup analysis according to high-volume vs. low-volume disease 39 
was performed.  40 
Evidence acquisition: A systematic review of PubMed/Medline, Embase, and 41 
proceedings of main International meetings was performed in June 2015 and updated in 42 
August 2015. Three trials were selected for inclusion. 43 
Evidence synthesis: Overall, 2951 patients were included in the 3 trials. Two trials 44 
enrolled only metastatic patients, while in the third trial 61% were metastatic: overall, 45 
metastatic patients were 2262 (951 docetaxel+ADT, 1311 ADT alone). Most patients had a 46 
good performance status. In metastatic patients, the addition of docetaxel was associated 47 
with improved OS (hazard ratio [HR] 0.73, 95%CI 0.60–0.90, p=0.002), with non significant 48 
heterogeneity among the 3 trials. Considering the whole study population (2951 patients), 49 
addition of docetaxel was associated with a similar OS improvement (HR 0.74, 95%CI 50 
0.61–0.91, p=0.003). Although with limited statistical power, no significant interaction was 51 
demonstrated between the addition of docetaxel and the high or low volume of disease 52 
(p=0.5). The addition of docetaxel was associated with improvement in progression-free 53 
survival (metastatic patients: HR 0.63, 95%CI 0.57–0.70, p<0.001).  54 
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Conclusions: This meta-analysis shows a significant OS benefit from concomitant 55 
administration of docetaxel and ADT in patients with metastatic, hormone-sensitive 56 
prostate cancer.  57 
Patient summary: We synthesized the evidence available about the early administration 58 
of docetaxel in patients starting hormonal treatment for metastatic prostate cancer. Based 59 
on results of this meta-analysis, we believe that the combination of chemotherapy and 60 
hormonal treatment should be considered in fit patients.  61 
62 
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 63 
Introduction 64 
Prostate cancer is the second most frequently diagnosed cancer in men and is the 65 
second leading cause of cancer death in male patients in United States and Europe [1]. 66 
Although localized prostate cancer may be successfully treated with radical prostatectomy 67 
and external beam radiation, many patients will subsequently develop metastatic disease 68 
[2]. In addition, in the United States, the proportion of patients presenting with advanced 69 
stage at first diagnosis of prostate cancer is 4-5% for distant disease and 10-12% for 70 
regional disease [3]. Androgen deprivation therapy (ADT) by medical or surgical castration 71 
is the mainstay of treatment for locally advanced and metastatic prostate cancer, because 72 
androgen receptor (AR) pathway plays a key role in the development and progression of 73 
prostate cancer cells [4]. Although ADT is able to induce biochemical and clinical response 74 
in more than 90% of patients, after a median of 24-36 months patients experience 75 
progression to castration-resistant prostate cancer (CRPC), despite persisting low 76 
testosterone levels [5].  77 
Until very recently, chemotherapy with docetaxel has been the only effective 78 
treatment for CRPC patients. In detail, the randomized clinical trial (RCT) TAX327 79 
demonstrated that docetaxel plus prednisone prolonged overall survival (OS) compared to 80 
mitoxantrone plus prednisone [6]. Another RCT, the SWOG-9916 study, also 81 
demonstrated that the treatment with docetaxel, estramustine and dexamethasone 82 
increased median OS by two months compared to mitoxantrone and prednisone [7]. 83 
Based on these results, docetaxel was the first cytotoxic drug to demonstrate an 84 
improvement in OS in prostate cancer. More recently, several new agents, able to modify 85 
the natural history of disease, have been introduced in clinical practice. Results from 86 
phase III trials have demonstrated the efficacy of two new-generation hormonal therapies 87 
(abiraterone [8] and enzalutamide [9]), an immunotherapy (sipuleucel-T [10]), a new 88 
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microtubule-targeting chemotherapy (cabazitaxel [11]) and an alpha-emitter (radium 223 89 
[12]), all able to prolong OS.  90 
Nowadays, progression of CRPC is known to be due to the onset of a number of 91 
resistance mechanism induced by the selective pressure of endocrine therapy [13-18]. 92 
Castration is able to induce clonal selection and subsequent growth of androgen-93 
independent cellular clones [19]. Hormone-sensitive prostate cancer should be considered 94 
a heterogeneous disease, characterized by the coexistence of both AR-positive and AR-95 
negative tumor cells.  96 
In this biological context, patients with hormone-sensitive prostate cancer may 97 
benefit of chemotherapy in association with endocrine therapy, targeting also AR-negative 98 
cells and delaying the development of resistance mechanisms. In the “pre-docetaxel” era, 99 
several RCTs investigated the combination of endocrine therapy with other cytotoxic drugs 100 
in hormone-sensitive prostate cancer patients, but none of these studies showed a 101 
significant and convincing advantage [20,21]. In the last two years, the results of three 102 
different clinical trials (GETUG-AFU 15 [22], CHAARTED – E3805 [23] and STAMPEDE 103 
[24]), that investigated the combination of docetaxel and ADT in hormone sensitive 104 
disease, have been made available to scientific community.  105 
The aim of this systematic review is to conduct a meta-analysis of RCTs that 106 
evaluated the combination of docetaxel with ADT vs. ADT alone, in hormone-sensitive 107 
metastatic prostate cancer, in order to assess the impact of this therapeutic option in terms 108 
of overall survival.109 
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 110 
Evidence acquisition 111 
Identification of eligible trials  112 
Full protocol of the review is available on request from the corresponding author. 113 
Search was performed in June 2015 and updated in August 2015, to identify all 114 
randomized trials testing the addition of docetaxel to ADT in patients with hormone-naive 115 
metastatic prostate cancer. Literature search was performed using PubMed, EMBASE, 116 
Medline, Cochrane Library. The following key-words were used: (prostate cancer) AND 117 
docetaxel AND (random*). References of the selected articles were also checked to 118 
identify further eligible trials. Furthermore, proceedings of the main International meetings 119 
(American Society of Clinical Oncology [ASCO] annual meeting, ASCO Genitourinary 120 
symposium, European Society of Medical Oncology, European Association of Urology), 121 
were searched from 2010 onwards for relevant abstracts. Trials enrolling both patients with 122 
metastatic disease and patients without metastases were eligible (details about subgroups 123 
were collected as specified below). Trials enrolling only patients without metastases 124 
[25,26] were excluded. When more than one report was available describing results of the 125 
same trial, the most recent information (corresponding to a longer follow-up and a higher 126 
number of events) was considered in the analysis. 127 
 128 
Data collection and study quality 129 
For each eligible trial, the following data were collected, if available:  130 
• main inclusion criteria: age, performance status, stage, Gleason score, prostate-131 
specific antigen (PSA) at randomization, presence of visceral metastases, 132 
volume(high vs. low) of metastatic disease, previous treatments;  133 
• details of study treatment: type of ADT allowed, schedule and number of cycles of 134 
docetaxel planned in experimental arm, timing of docetaxel start compared to ADT 135 
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initiation in experimental arm, number of docetaxel cycles actually administered 136 
(median, range), proportion of patients completing planned docetaxel cycles, 137 
proportion of patients needing dose reduction of docetaxel;  138 
• study design: primary endpoint, study hypothesis; 139 
• patients’ enrolment and follow-up: date of start and date of end of accrual; number 140 
of patients assigned to experimental arm (docetaxel + ADT), number of patients 141 
assigned to control arm (ADT alone), median follow-up; 142 
• Overall survival [OS]: number of deaths in each arm, median OS, hazard ratio with 143 
95% confidence interval, p value, details of subgroup analysis of metastatic patients 144 
(for trials enrolling both M0 and M1 patients), details of subgroup analysis in “high-145 
volume” patients and “low-volume” patients;  146 
• Progression-free survival [PFS]: number of events in each arm, median PFS, 147 
hazard ratio with 95% confidence interval, p value, details of subgroup analysis of 148 
metastatic patients (for trials enrolling both M0 and M1 patients).  149 
For each study, the quality of the randomization process was evaluated based on the 150 
information available in the publication [22, 23] or in the study protocol [24].  151 
 152 
Statistical Methods 153 
After data were abstracted, analysis was performed the Review Manager (RevMan 154 
5.3) software. In all the trials included, efficacy data were analysed from all randomly 155 
assigned patients on an intention-to-treat basis. Primary endpoint of the meta-analysis was 156 
overall survival. Secondary endpoint was biochemical progression-free survival (bPFS). 157 
Definition of bPFS was different in the three trials and is reported in Supplemental table 158 
A1.  159 
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For both overall survival and bPFS, summary measure was hazard ratio (with 95% 160 
confidence interval). A random-effects model was applied. Statistical heterogeneity 161 
between studies was examined using the χ2 test and the I2 statistic. 162 
Main analysis was performed considering the 3 comparisons of docetaxel + ADT vs. 163 
ADT alone. In one trial [24], a further experimental arm was reported, testing the addition 164 
of docetaxel + zoledronic acid to ADT alone. Since the addition of zoledronic acid alone 165 
did not show any significant efficacy compared to ADT, we decided to perform an 166 
exploratory analysis adding also this comparison to the analysis of docetaxel. However, 167 
since that trial used the same control arm for the two comparisons (docetaxel + ADT vs. 168 
ADT alone, and docetaxel + zoledronic acid + ADT vs. ADT alone), the weight of each 169 
comparison was reduced according to a correction factor equal to the number of events 170 
actually observed in the trial, divided by the number of events taken into account in the 171 
analysis (where the control arm was counted twice). This correction resulted in a 172 
prudential increase in the width of the confidence interval for the estimated hazard ratio of 173 
each comparison.  174 
For overall survival, the subgroup analysis of patients according to disease volume 175 
(“high-volume” vs “low-volume”) was available for two of the three trials [27,23]. In both 176 
trials, “high-volume” disease was defined as the presence of at least 4 bone lesions and at 177 
least 1 lesion in any bone beyond the spine / pelvis, or the presence of visceral 178 
metastasis. Patients without these conditions were classified as “low-volume”. No 179 
subgroup analysis of progression-free survival according to disease volume was available.  180 
    181 
Role of funding source 182 
There was no funding source for this review. All authors had full access to all the 183 
data and the corresponding author (MDM) had final responsibility for the decision to submit 184 
for publication.185 
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 186 
Evidence synthesis 187 
Characteristics and quality of the trials  188 
The selection process of trials eligible for the meta-analysis is reported in Supplemental 189 
Figure 1. In the search updated in August 2015, out of the 466 papers published in 190 
extenso, 464 were excluded, while two (GETUG-AFU 15 and CHAARTED – E3805) were 191 
found eligible for inclusion [22, 23]. One further eligible trial (STAMPEDE) was found 192 
searching the proceedings of the main International meetings [24]. Furthermore, an 193 
updated report of the already published GETUG-AFU 15 trial, with longer follow-up and a 194 
higher number of events for analysis, was available [27].    195 
Main characteristics of the three available trials are described in Table 1. In all the 196 
trials, patients assigned to experimental arm received docetaxel 75 mg/m2, for a maximum 197 
of 6 [23,24] or 9 cycles [22]. The maximum interval since ADT start allowed to start 198 
docetaxel ranged from 2 to 4 months: in the GETUG-AFU 15 trial about half of the patients 199 
had started ADT within 15 days of enrolment [22]; in the CHAARTED – E3805 trial, 200 
median time from ADT to randomization was slightly higher than 1 month in both arms 201 
[23].  202 
According to description available in the publication for 2 trials [22,23] and in the 203 
study protocol for the third trial [24], quality of randomization process was judged adequate 204 
in all the 3 trials.  205 
 206 
Patients’ characteristics 207 
Overall, 2951 patients were included in the 3 trials included in the meta-analysis, 208 
1181 (40%) assigned to docetaxel + ADT, and 1770 (60%) assigned to ADT alone (Table 209 
2). Main characteristics of the 2951 patients are described in Table 2. Patients were 210 
enrolled between October 2004 and March 2013. Median age was 63-65 years, and most 211 
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of the patients had a good performance status. Two of the trials [22,23] enrolled only 212 
metastatic patients, while in the STAMPEDE trial [24] metastatic patients were 61% of total 213 
study population: overall, metastatic patients were 2262 (951 docetaxel+ADT, 1311 ADT 214 
alone). Patients with metastatic disease at diagnosis were 71% in the GETUG-AFU 15 trial 215 
and 73% in the CHAARTED – E3805 trial; 94% of patients enrolled in the STAMPEDE trial 216 
had not received previous local therapy. Patients with high-volume disease were 48% in 217 
the GETUG-AFU 15 trial, and 65% in the CHAARTED – E3805 trial; this information was 218 
not available in the STAMPEDE trial.   219 
 220 
Treatment compliance and toxicity 221 
Median number of docetaxel cycles actually administered was 8 in the GETUG-AFU 222 
15 trial [22], 6 in the CHAARTED – E3805 [23] and 6 in the STAMPEDE trial [24]. 223 
Proportion of patients completing the planned number of cycles was 48% in the GETUG-224 
AFU 15 trial (9 planned cycles), 86% in the CHAARTED – E3805 trial (6 planned cycles) 225 
and 76% in the STAMPEDE trial (6 planned cycles). Proportion of patients needing dose 226 
reduction was 11% in the GETUG-AFU 15 trial and 26% in the CHAARTED –E3805 trial, 227 
while this information was not available in the report of the STAMPEDE trial. 228 
 The most common adverse events reported with the addition of docetaxel were 229 
haematologic toxicity (anemia, thrombocytopenia, neutropenia), fatigue, gastro-intestinal 230 
toxicity (nausea, vomiting, constipation, diarrhea), alopecia, sensory neuropathy, 231 
stomatitis/mucositis, nail changes and peripheral edema. In all the 3 trials, the addition of 232 
docetaxel was associated to higher incidence of febrile neutropenia: 8%, 6% and 12% in 233 
the GETUG-AFU 15, in the CHAARTED – E3805 and in the STAMPEDE trial, versus 0%, 234 
not reported and 1% with ADT alone in the 3 trials respectively.  235 
 236 
Overall survival 237 
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Number of events and OS data reported in each trial are summarized in Table 3. 238 
Overall, 916 deaths were recorded for the main comparison (docetaxel + ADT vs. ADT 239 
alone) in metastatic patients. As shown in Figure 1 (panel A), the addition of docetaxel to 240 
ADT in metastatic patients was associated with a statistically significant benefit in overall 241 
survival (hazard ratio [HR] 0.73, 95% confidence interval [CI] 0.60 – 0.90, p = 0.002). 242 
There was no evidence of statistically significant heterogeneity among the three trials (p = 243 
0.15, I² = 48%). In the whole study population, including also the minority of non-metastatic 244 
patients (Figure 1, panel B), the addition of docetaxel to ADT was associated with a 245 
similar, statistically significant benefit in overall survival (HR 0.74, 95% CI 0.61 – 0.91, p = 246 
0.003). Very similar results were obtained in the exploratory analysis including also the 247 
docetaxel + zoledronic acid arm of the STAMPEDE trial: HR 0.74 (95%CI 0.63 – 0.88, 248 
p<0.001) considering only metastatic patients (Figure 1, panel C), HR 0.76 (95%CI 0.64 – 249 
0.89, p=0.001) in all patients (Figure 1, panel D).  250 
Subgroup analysis was performed for metastatic patients with “high-volume” and 251 
“low-volume” disease enrolled in the GETUG-AFU 15 and in the CHAARTED – E3805 trial 252 
(Figure 2). The test for difference of efficacy among the two subgroups did not 253 
demonstrate a statistically significant interaction (p=0.5). Hazard ratio for the addition of 254 
docetaxel to ADT was 0.67 (95% CI 0.51 – 0.88) in patients with “high-volume” disease 255 
and 0.80 (95% CI 0.49 – 1.32) in patients with “low-volume” disease.  256 
 257 
Progression-free survival 258 
As shown in Figure 3 (panel A), the addition of docetaxel to ADT in metastatic 259 
patients was associated with a statistically significant benefit in progression-free survival 260 
(HR 0.63, 95% CI 0.57 – 0.70, p < 0.001), without significant heterogeneity among the 261 
three trials (p = 0.7, I² = 0%). The same benefit was shown considering the whole study 262 
population, including the minority of patients without metastates (HR 0.63, 95% CI 0.57 – 263 
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0.70, p < 0.001) (Figure 3, panel B). Very similar results were obtained in the exploratory 264 
analysis including also the docetaxel + zoledronic acid arm of the STAMPEDE trial: HR 265 
0.63 (95%CI 0.56 – 0.70, p<0.001) in metastatic patients (Figure 3, panel C), HR 0.63 266 
(95%CI 0.57 – 0.70, p<0.001) in all patients (Figure 3, panel D). 267 
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 268 
Conclusions. 269 
This meta-analysis shows that the addition of docetaxel to ADT in patients with 270 
metastatic, hormone-sensitive prostate cancer is associated with a significant 271 
improvement in overall survival and progression-free survival.  272 
A quantitative synthesis of the evidence currently available about this treatment 273 
strategy can be really helpful for clinical decisions, because three recent, different phase III 274 
trials (GETUG-AFU-15 [22,27], CHAARTED – E3805 [23], STAMPEDE [24]) tested the 275 
activity of docetaxel in combination with endocrine therapy in the “early” setting of 276 
hormone-sensitive prostate cancer. To the best of our knowledge, there are no other trials 277 
conducted with docetaxel in the same setting, and this meta-analysis represents the 278 
synthesis of all the evidence produced to date. Notably, in GETUG-AFU-15 trial, the first 279 
trial to be published, the concomitant administration of docetaxel with ADT versus ADT 280 
alone did not show a significant impact in terms of OS [22, 27]. On the contrary, 281 
CHAARTED – E3805 trial showed a significant OS improvement for ADT plus docetaxel 282 
[28], adding fuel to the scientific debate about the opportunity of this therapeutic option in 283 
hormone-sensitive prostate cancer patients. In our meta-analysis, that also included the 284 
recent results of the “third- comer”, the STAMPEDE trial [24], the addition of docetaxel to 285 
ADT in metastatic patients was associated with a statistically significant increase in overall 286 
survival, with a moderate, non significant heterogeneity among the three available RCTs. 287 
Of note, the absence of statistical heterogeneity increases the validity of the result, 288 
allowing a global, unambiguous interpretation of all the evidence available. Of course, a 289 
meta-analysis based on individual patient data (IPD) would represent the best synthesis of 290 
evidence, allowing for data checking, updated follow-up compared to publications, 291 
calculation and comparison of times to events, and for investigation of treatment 292 
heterogeneity in subgroups [29]. However, in the absence of IPD meta-analysis, a meta-293 
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analysis based on abstracted data can be considered an acceptable surrogate, allowing a 294 
timely synthesis of all the available trials.   295 
The efficacy showed by docetaxel in combination with ADT in hormone-sensitive 296 
patients is not surprising due to strong biological basis. Recent evidences show that one of 297 
the mechanisms responsible for progression from hormone-sensitive to castration-298 
resistant phase of disease is the clonal selection and proliferation of pre-existing AR-299 
independent cells, able to survive in a low androgen levels environment [19]. Therefore it 300 
is reasonable to assume that, since its onset, prostate cancer is a heterogeneous disease 301 
where coexist AR-positive and AR-negative cells [19, 30]. Both these cellular clones are 302 
likely involved in progression to castration-resistant disease [19]. Docetaxel administration 303 
concurrent to ADT in hormone-sensitive prostate cancer patients allows to inhibit the 304 
growth of the pre-existing AR-insensitive clones, killing these cells earlier when they are 305 
still a small number and before the development of multiple escape mechanisms. 306 
Moreover, preclinical data show that the adaptive response to ADT by prostate cancer 307 
cells is mediated by both ligand-dependent AR activation and ligand-independent AR 308 
activation and by mechanisms of progression bypassing AR signaling [19,31]. Taxanes are 309 
able to interfere with several steps of these resistance mechanisms. Emerging preclinical 310 
data demonstrated that taxanes could inhibit AR signaling pathway [32]. In fact, these 311 
cytotoxic drugs interfere with polymerization of microtubules, blocking AR nuclear 312 
translocation and AR-induced gene expression [32,33]. Therefore docetaxel could act 313 
synergistically with endocrine therapy, because it impairs AR activity [32,33]. Additionally, 314 
chemotherapy may also kill cells that escape ADT through activation of AR-independent 315 
survival pathways [34].   316 
From a clinical point of view, there are several potential advantages in administering 317 
chemotherapy to metastatic prostate cancer patients in an early phase of disease. In the 318 
hormone-sensitive setting, patients are, on average, in better clinical conditions compared 319 
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to castration-resistant setting, due to lower burden of disease. Consequently, they are able 320 
to better tolerate chemotherapy and to maintain adequate drug dose intensity. Moreover, a 321 
greater number of patients is eligible for chemotherapy; in the castration-resistant setting, 322 
on the contrary, a relevant number of patients cannot receive chemotherapy, due to 323 
worsening of performance status and clinical conditions.  324 
 Our meta-analysis shows an improvement in OS that is not only statistically 325 
significant, but also clinically relevant. The addition of docetaxel to ADT is associated with 326 
a 27% reduction in the risk of death of metastatic patients (Hazard Ratio 0.73), and the 327 
reduction in the risk of death is as high as 33% in patients with high-volume disease 328 
(Hazard Ratio 0.67). In absolute terms, such a benefit is rarely obtained in the setting of 329 
advanced solid tumors: difference in median OS for metastatic patients was more than 13 330 
months in the CHAARTED – E3805 trial [23], and 18 months in the STAMPEDE trial [24]. 331 
Much smaller benefits have been often judged sufficient to change clinical practice in 332 
metastatic prostate cancer, as well as in other settings. However, we recognize that a 333 
careful selection of patients to be treated with up-front docetaxel is essential for a 334 
favorable benefit / risk ratio. Subgroup data of the CHAARTED trial had suggested that the 335 
benefit associated with concomitant administration of docetaxel with ADT, at least in early 336 
analysis, was more pronounced in patients with “high-volume” disease than in patients 337 
with “low-volume” disease [28, 23]. Definition of “high-volume” disease follows previous 338 
robust data showing that, in patients with hormone-sensitive disease, the presence of 339 
extensive disease (visceral metastases or appendicular skeletal involvement) is related to 340 
a worse prognosis [35-37]. In both the CHAARTED – E3805 (based on a prospective 341 
definition) and the GETUG-AFU 15 (based on a retrospective assessment), “high-volume” 342 
disease was defined as the presence of visceral metastases or the presence of at least 4 343 
bone lesions, with 1 or more lesions in any bone beyond the spine / pelvis. However, 344 
based on subgroup data available for those 2 trials [23, 27], we performed an exploratory 345 
16 
 
 
 
analysis of treatment efficacy according to disease volume: although the statistical test for 346 
interaction is characterized by a limited statistical power, we did not demonstrate a 347 
significant interaction between disease volume and treatment efficacy. Importantly, this 348 
absence of significant interaction does not allow to state that the addition of docetaxel to 349 
ADT is not effective in patients with low-volume metastatic disease. A longer follow-up with 350 
a higher number of events in these latter patients, together with the availability of this 351 
subgroup analysis also in the STAMPEDE trial, could increase the statistical power of the 352 
analysis. With the currently available evidence, however, no definitive statement can be 353 
made about the interaction between docetaxel efficacy and disease volume.  354 
 With the exception of a subgroup of patients eligible for the STAMPEDE trial, the 355 
majority of patients included in the 3 trials had metastatic disease. Other trials have tested 356 
the efficacy of the addition of docetaxel to androgen deprivation therapy in patients with 357 
high-risk, localized prostate cancer [25,26]. However, the definition of the role of docetaxel 358 
in patients with high-risk, localized prostate cancer is beyond the scope of this meta-359 
analysis.  360 
 Of course, particular attention should be given to toxicity associated with 361 
combination treatment. In the experimental arm of GETUG-AFU 15 study, four treatment-362 
related deaths were reported (one due to febrile neutropenia, one neutropenia with 363 
infection, one multiorgan failure, and one pulmonary embolism), compared to no 364 
treatment-related deaths with ADT alone [22]. In CHAARTED – E3805 trial, only one 365 
treatment-related death (sudden death) occurred in combination arm [23]. Although these 366 
numbers, overall considered, are quite reassuring, it is well known that patients enrolled in 367 
clinical trials are selected compared to all patients treated in daily clinical practice, in terms 368 
of age, performance status, comorbidities. For instance, patients older than 70 years are a 369 
relevant proportion of those treated in clinical practice, but were quite under-represented in 370 
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the 3 trials. In the CHAARTED trial, subgroup analysis according to age supports 371 
docetaxel efficacy also in elderly patients, but they represented only 23% of total study 372 
population [23]. Although a potential explanation is that the age of metastatic presentation 373 
of patients eligible for these 3 trials could be younger than the whole population of patients 374 
with new diagnosis of earlier stage prostate cancer, we believe that the main reason for 375 
the under-representation of elderly patients in the trials included in this meta-analysis is 376 
the selection bias, because patients had to be fit enough to receive chemotherapy with 377 
docetaxel [38]. In any case, chemotherapy toxicity is often worse in the “real world” 378 
population, compared with the toxicity reported in clinical trials. Therefore, clinicians must 379 
properly take into account some relevant clinical factors (performance status, concomitant 380 
diseases) before considering the addition of docetaxel to ADT, in order to reduce the risk 381 
of severe toxicity, that could negatively affect quality of life and, in worst cases, survival.  382 
 In conclusion, our meta-analysis clearly shows a significant impact on overall 383 
survival with the concomitant administration of docetaxel and androgen-deprivation 384 
treatment in patients with metastatic, hormone-sensitive prostate cancer patients. 385 
Considering the absence of heterogeneity among the available trials, and the balance 386 
between magnitude of efficacy and risk of toxicity, combination of chemotherapy and 387 
hormonal treatment should be reasonably offered to patients with metastatic disease, if 388 
judged eligible for chemotherapy. Higher statistical power would be needed to better 389 
understand the interaction, if any, between the efficacy of docetaxel and the volume of 390 
disease.  391 
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 392 
Figure legends. 393 
 394 
Figure 1. Forest plots of hazard ratios for overall survival from three randomized trials of 395 
docetaxel added to androgen-deprivation therapy (ADT), compared with ADT alone, in 396 
patients with advanced, hormone-sensitive prostate cancer. Pooled HRs were computed 397 
using random-effect models. The bars indicate 95% confidence intervals (CI). Panel A 398 
(only metastatic patients) and panel B (all randomized patients) consider only comparisons 399 
between docetaxel + ADT vs. ADT alone. Panel C (only metastatic patients) and panel D 400 
(all randomized patients) show a sensitivity analysis considering also the comparison of 401 
docetaxel + zoledronic acid + ADT vs. ADT alone in the STAMPEDE trial.   402 
 403 
Figure 2. Forest plots of hazard ratios for overall survival (subgroup analysis according to 404 
disease volume: patients with “high-volume” disease and patients with “low-volume” 405 
disease) in two randomized trials of docetaxel added to androgen-deprivation therapy 406 
(ADT), compared with ADT alone, in patients with metastatic, hormone-sensitive prostate 407 
cancer. Pooled HRs were computed using random-effect models. The bars indicate 95% 408 
confidence intervals (CI). Definition of “high-volume” disease and “low-volume” disease is 409 
detailed in the text. 410 
 411 
Figure 3. Forest plots of hazard ratios for biochemical progression-free survival from three 412 
randomized trials of docetaxel added to androgen-deprivation therapy (ADT), compared 413 
with ADT alone, in patients with advanced, hormone-sensitive prostate cancer. Pooled 414 
HRs were computed using random-effect models. The bars indicate 95% confidence 415 
intervals (CI). Panel A (only metastatic patients) and panel B (all randomized patients) 416 
consider only comparisons between docetaxel + ADT vs. ADT alone. Panel C (only 417 
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metastatic patients) and panel D (all randomized patients) show a sensitivity analysis 418 
considering also the comparison of docetaxel + zoledronic acid + ADT vs. ADT alone in 419 
the STAMPEDE trial. 420 
 421 
Supplemental Figure 1.  Selection process of randomized trials eligible for inclusion in 422 
the meta-analysis.  423 
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AB
C
D
Outcome: overall survival
(all randomized patients)
Outcome: overall survival
(only metastatic patients)
Outcome: overall survival
(all randomized patients)
Sensitivity analysis including the docetaxel + zoledronic acid arm
Outcome: overall survival
(only metastatic patients)
Sensitivity analysis including the docetaxel + zoledronic acid arm

AB
C
D
Outcome: progression-free survival
(all randomized patients)
Outcome: progression-free survival
(only metastatic patients)
Outcome: progression-free survival
(all randomized patients)
Sensitivity analysis including the docetaxel + zoledronic acid arm
Outcome: progression-free survival
(only metastatic patients)
Sensitivity analysis including the docetaxel + zoledronic acid arm
Table 1. Characteristics of the 3 trials included in the meta-analysis 
 GETUG-AFU 15 
[22,27] 
CHAARTED – E3805 
[23] 
STAMPEDE 
[24] 
Main inclusion criteria 
Age Older than 18. 
No upper limit 
declared in the 
methods. 
Both younger than 70 
and older than 70 
were eligible 
(stratification criteria). 
Not specified. 
Performance status  Karnofsky >= 70 ECOG 0-2 
(2 only if due to 
prostate cancer) 
(0-1 vs 2 stratification 
criteria) 
WHO 0-2 
Stage Metastatic prostate 
cancer 
(High-volume vs low-
volume assessed 
retrospectively) 
Metastatic prostate 
cancer  
(High-volume vs low-
volume stratification 
criteria)* 
Prostate cancer if 
metastatic, node-positive 
or >=2 among: 
• Stage T3/T4 
• PSA>=40ng/ml 
• Gleason 8-10 
Previous treatment Previous 
chemotherapy for 
metastatic disease 
was not allowed.  
In the neoadjuvant 
and adjuvant settings 
or in the context of 
isolated PSA 
increase, previous 
chemotherapy or 
ADT, or both, were 
allowed, with the 
condition that the 
treatment had been 
discontinued at least 
12 months before 
inclusion in the study. 
No prior docetaxel 
was allowed. 
Adjuvant ADT was 
allowed, but <24 
months (<=12 months 
vs >12 months 
stratification criteria) 
and interval between 
end of adjuvant 
treatment and 
progression > 12 
months. 
 
Prior chemotherapy was 
not allowed. 
Long-term anti-androgen 
therapy was not allowed. 
Short periods of prior 
anti-androgens to cover 
tumour flare were 
allowed. 
Adjuvant or neo-adjuvant 
hormone therapy had to 
be completed at least 12  
months before the trial, 
and duration of 
therapy had to be 
no longer than 12 
months. 
 
(table continues in next page) 
Table 1. (continued) 
 GETUG+AFU 15 
[22,26] 
CHAARTED – E3805 
[23] 
STAMPEDE [24] 
Treatment 
ADT (both arms) Orchiectomy or 
LHRH agonists, 
alone or combined 
with non-steroidal 
antiandrogens 
Medical or surgical 
castration. Use of a 
nonsteroidal 
antiandrogen at the 
time of initiation of 
therapy was at the 
discretion of the 
investigator.. 
 
LHRH analogues or 
LHRH antagonists, or 
bilateral orchidectomy 
according to local 
practice 
Docetaxel  
(experimental arm) 
Docetaxel (75 mg/m2 
i.v. day 1 q3w);  
up to 9 cycles. 
Standard 
corticosteroids 
premedication, no 
daily prednisone. 
Docetaxel (75 mg/m2 
i.v. day 1 q3w);  
up to 6 cycles. 
Standard 
dexamethasone 
premedication, no 
daily prednisone. 
Docetaxel (75 mg/m2 i.v. 
day 1 q3w);  
up to 6 cycles. 
Standard dexamethasone 
premedication, daily 
prednisolone 10 mg. 
Timing of treatment Docetaxel within 2 
months of ADT start. 
Docetaxel within 4 
months of ADTstart. 
Randomization within 12 
weeks of ADT start.  
Study design 
Primary endpoint Overall survival Overall survival Overall survival 
Hypothesis Increase in 3-yr OS 
from 50% to 65% 
33% increase in 
median OS 
(from 33 to 44 months 
in high-volume,  
from 67 to 89 months 
in low-volume) 
25% increase in overall 
survival. 
Patients’ enrollment and follow-up 
Accrual start October 2004 July 2006 October 2005 
Accrual stop December 2008 November 2012 March 2013 
Number of patients     
ADT alone 193 393 1184 
ADT + docetaxel 192 397 592 
ADT + docetaxel + 
zoledronic acid 
  593 
Median follow-up 82.9 months 28,9 months n.a. 
ADT: androgen-deprivation treatment; ECOG: Eastern Cooperative Oncology Group; WHO: World Health 
Organization; PSA: prostate-specific antigen; LHRH: luteinizing hormone – releasing hormone; OS: overall 
survival; n.a.: not available. 
*after amendment. In the initial protocol version, only high-volume patients were eligible.
Table 2. Main characteristics of enrolled patients 
 GETUG-AFU 15 
[22,27] 
CHAARTED – E3805 
[23] 
STAMPEDE [24] 
(whole trial*) 
Age  
ADT alone: 
Median 64 years 
(IQR 58-70) 
 
 
ADT alone: 
Median 63 years 
(range 39-91) 
 Median 65 years 
(range 40-84)  
ADT +docetaxel:  
Median 63 years 
(IQR 57-68) 
 
 
ADT + docetaxel: 
Median 64 years 
(range 36-88) 
 
Performance status   
ADT alone: 
Median Karnofsky 
100% 
(IQR range 90%-100%) 
 
 
ADT alone: 
ECOG 0: 69% 
ECOG 1: 29% 
ECOG 2: 1.5% 
 WHO PS0: 76%  WHO PS1: 21%  
WHO PS2: 1%   ADT+ docetaxel: 
Median Karnofsky 
100% 
(IQR 90%-100%) 
 
 
ADT + docetaxel: 
ECOG 0: 70% 
ECOG 1: 29% 
ECOG 2: 1.5% 
 
Gleason score   
ADT alone 
(unknown 2/193): 
Gleason 2-6: 7% 
Gleason 7: 34% 
Gleason 8-10: 59% 
 
ADT alone 
(unknown 46/393): 
Gleason 4-6: 6% 
Gleason 7: 24% 
Gleason 8-10: 70% n.a.  
ADT+ docetaxel 
(unknown 5/192): 
Gleason 2-6: 10% 
Gleason 7: 35% 
Gleason 8-10: 55% 
 
ADT + docetaxel 
(unknown 39/393): 
Gleason 4-6: 6% 
Gleason 7: 27% 
Gleason 8-10: 67% 
PSA at 
randomization  
 
ADT alone: 
Median 26 
(IQR 5 – 127) 
 
ADT alone: 
Median 52.1 
(range 0.1 – 8056.0) 
n.a.  
ADT+ docetaxel: 
Median 27 
(IQR 5 – 106) 
 
ADT + docetaxel: 
Median 50.9 
(range 0.2 – 8540.1) 
Stage  
ADT alone: 
100% metastatic 
 
ADT alone: 
100% metastatic 
 61% Metastatic 15% Node positive M0 
24% N0 M0   ADT + docetaxel: 
100% metastatic 
 
 
ADT + docetaxel: 
100% metastatic 
Metastatic at 
diagnosis 
 
ADT alone: 
67%  
 
 
ADT alone: 
73% had not received 
prior local therapy 
 
94% of randomized 
patients had not 
received previous local 
therapy  
 
ADT + docetaxel: 
76%  
 
 
ADT + docetaxel: 
73% had not received 
prior local therapy 
 
Presence of visceral 
metastases 
 
ADT alone: 
11% lung 
2% liver 
 
 
ADT alone: 
17% 
 
n.a.   
ADT + docetaxel: 
11% lung 
5% liver 
 
 
ADT + docetaxel: 
14% 
 
Volume of 
metastatic disease 
 
ADT alone: 
52% low-volume 
48% high-volume 
 
 
ADT alone: 
36% low-volume 
64% high-volume 
 n.a.   
ADT + docetaxel: 
53% low-volume 
47% high-volume  
 
 
ADT + docetaxel: 
34% low-volume 
66% high-volume 
 
IQR: interquartile range; ADT: androgen- deprivation treatment; PS: performance status; PSA: prostate 
specific antigen; M0: absence of distant metastases; N0: absence of nodal metastases; n.a.: not applicable. 
*details by arm are not provided
Table 3. Overall survival data reported in each single trial. 
 GETUG-AFU 15 
[22,27] 
CHAARTED – E3805  
[23] 
STAMPEDE [24] 
   All patients Metastatic patients 
Number of patients      
 ADT alone 193 393 1184 725 
 ADT + docetaxel 192 397 592 362 
 ADT + docetaxel + zoledronic acid   593 365 
Number of events      
 ADT alone 
212 (both arms) 
136 405 343  
 ADT + docetaxel 101 165 134 
 ADT + docetaxel + zoledronic acid   181 152 
Median OS     
 ADT alone 46.5 months 44.0 months 67 months 43 months 
 ADT + docetaxel 60.9 months 57.6 months 77 months 65 months 
 ADT + docetaxel + zoledronic acid   72 months n.a. 
Hazard Ratio (95% confidence interval)     
 ADT + docetaxel vs. ADT alone 
0.9 
(0.7 – 1.2), 
p=0.4 
0.61 
(0.47 – 0.80), 
P<0.001 
0.76 
(0.63 – 0.91), 
p=0.003 
0.73 
(0.59 – 0.89), 
p=0.002 
 ADT + docetaxel + zoledronic acid vs. ADT alone   
0.81 
(0.68 – 0.97), 
p=0.02 
0.78 
(0.65 – 0.95), 
p=n.a. 
ADT: androgen-deprivation treatment; n.a.: not available.
Supplementary Table A1. Definition of biochemical progression-free survival  
GETUG-AFU 15 [22] CHAARTED – E3805 [23] Stampede [24] 
 
Time to PSA progression, 
clinical progression or death. 
Biochemical progression was 
defined with the PSA Working 
Group definition: a previous 
confirmed PSA decrease of at 
least 50% and an increase of 
at least 50% above the nadir, 
with a minimum increase of 5 
ng/mL. For patients without a 
previous PSA decrease of 
50%, progression was defined 
as a PSA increase of at least 
25% above the nadir and of at 
least 5 ng/mL. 
  
 
Time to castration-resistant 
prostate cancer: time until 
documented clinical or 
serologic progression with 
a testosterone level of less 
than 50 ng per deciliter (or 
source documentation of 
medical castration or 
surgical castration). 
Disease progression on 
imaging was determined 
according to the Response 
Evaluation Criteria in Solid 
Tumors (RECIST), version 
1.0. 
Serologic progression was 
defined as an increase in 
the PSA level of more than 
50% above the nadir 
reached after the initiation 
of ADT, with two 
consecutive increases at 
least 2 weeks apart. The 
date of a first recorded 
increase of more than 50% 
above the nadir was 
deemed the date of 
progression. If the nadir 
level was less than 2 ng 
per milliliter, a minimum 
increase of more than 2 ng 
per milliliter was required. 
 
Failure-free survival: 
First event among PSA 
failure, local failure, lymph 
node failure, distant 
metastases, prostate 
cancer death.  
PSA failure definition:  
If PSA fall >= 50%: 
• 24 week nadir + 50% 
and  
• >4 ng/ml 
If PSA fall < 50%: 
• Failure at t=0 
PSA: prostate-specific antigen; ADT: androgen deprivation therapy. 
